Life Brand products were created, and the Companys first private label products are introduced
Conclusion: NASH risk alleles were prevalent in the MAESTRO-NASH population and did not influence the treatment response to resmetirom Disclosures: Naga Chalasani: Madrigal: Consultant, Zydus, Ipsen, Pfizer, Merck, Altimmune, GSK: Consultant, Exact Sciences: Grant/Research Support, NIH: Grant/Research Support, Dominic Labriola: Nothing to Disclose, Rebecca Taub: Madrigal Pharmaceuticals: Employee, Madrigal Pharmaceuticals: Stock - publicly traded company, Madrigal Pharmaceuticals: Executive role, Quentin Anstee: AstraZeneca, Boehringer Ingelheim, Intercept.: Grant/Research Support, Alimentiv, Akero, AstraZeneca, Axcella, 89Bio: Consultant, Boehringer Ingelheim, Bristol Myers Squibb, Corcept: Consultant, Enyo Pharma, Galmed, Genfit, Genentech, Gilead, GlaxoSmithKl: Consultant, Hanmi, HistoIndex, Intercept, Inventiva, Ionis, IQVIA, Janss: Consultant, Madrigal, Medpace, Merck, Metadeq, NGMBio, North Sea T: Consultant, Novartis, Novo Nordisk, PathAI, Pfizer, Pharmanest: Consultant, Poxel, Prosciento, Resolution Therapeutics, Roche,: Consultant, Ridgeline Therapeutics, RTI, Shionogi, Terns: Consultant, Fishawack, Integritas Communications, Kenes,: Speaking and Teaching, Novo Nordisk, Madrigal, Medscape, Springer Healthcare: Speaking and Teaching, Elsevier Ltd: Royalties or patent beneficiary 2071 APPLYING THE METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) NOMENCLATURE WITH NATURAL LANGUAGE PROCESSING IN A NATIONAL COHORT Binu John 1 Dustin Bastaich 2 Catherine Mezzacappa 3 Raphaella Ferreira 4 Austen Hentschel 5 Andres Samos 5 Nadim Mahmud 6 Tamar Taddei 3 David Kaplan 7 Marina Serper 8 Bassam Dahman 2 , 1 Miami VA and University of Miami, 2 Virginia Commonwealth University, 3 Yale University, 4 Larkin Community Hospital, 5 Florida International University, 6 Hospital of the University of Pennsylvania, 7 University of Pennsylvania, 8 University of Pennsylvania Health System Background: Although metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD with increased alcohol intake (MetALD) are identified as a separate clinical entities, tools to identify patients from electronic health records are lacking
,
E.Garcia-RuizH
doi: 10.1016/j.beem.2022.101616 28 WeaverCMGordonCMJanzKFKalkwarfHJLappeJMLewisRet al
